Background/Objectives:Hepatocellular carcinoma (HCC) remains a significant global health issue due to its high mortality rate and resistance to standard treatments. Sorafenib, the first-line systemic therapy for unresectable HCC, shows limited effectiveness due to resistance and severe side effects. Recent studies suggest that combining sorafenib with immunotherapy, particularly natural killer (NK) cells, may improve treatment outcomes.Methods:This study examined the effectiveness of sorafenib combined with NK cells pretreated with interleukin-12 (IL-12) and interleukin-18 (IL-18) in a rat HCC model. Tumor progression and treatment outcomes were assessed using MRI and histological analysis.Results:The results show that combination therapy significantly reduced tumor growth, increased tumor cell density, and inhibited angiogenesis and fibrosis in the tumor microenvironment. The sorafenib- and IL-12/IL-18-pretreated NK cell combination enhanced tumor inhibition by overcoming drug resistance and modulating the immune response.Conclusions:This study suggests that this combination therapy could be a promising strategy for treating HCC, offering both direct antitumor effects and modification of the tumor microenvironment for better clinical outcomes.
背景/目的：肝细胞癌（HCC）因其高死亡率及对标准治疗的耐药性，仍是全球重大健康问题。索拉非尼作为不可切除HCC的一线全身治疗方案，因耐药性和严重副作用而疗效有限。近期研究表明，将索拉非尼与免疫疗法（特别是自然杀伤细胞）联合应用可能改善治疗效果。 方法：本研究在大鼠HCC模型中评估了索拉非尼联合白细胞介素-12（IL-12）和白细胞介素-18（IL-18）预处理的自然杀伤细胞的疗效。通过磁共振成像和组织学分析评估肿瘤进展及治疗效果。 结果：联合治疗显著抑制了肿瘤生长，提高了肿瘤细胞密度，并抑制了肿瘤微环境中的血管生成和纤维化。索拉非尼与IL-12/IL-18预处理的自然杀伤细胞联合疗法通过克服耐药性和调节免疫反应，增强了肿瘤抑制效果。 结论：本研究表明该联合疗法可能成为治疗HCC的有效策略，既能直接发挥抗肿瘤作用，又能改善肿瘤微环境，从而获得更好的临床疗效。
肿瘤(癌症)患者之家